| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours
|
Baruchel, Sylvain
|
|
2009
|
45 |
13 |
p. 2352-2359
8 p.
|
artikel
|
| 2 |
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: A combined analysis of 10 EORTC trials
|
Francart, J.
|
|
2009
|
45 |
13 |
p. 2304-2311
8 p.
|
artikel
|
| 3 |
Calendar
|
|
|
2009
|
45 |
13 |
p. I-
1 p.
|
artikel
|
| 4 |
Capecitabine and vinorelbine in metastatic breast cancer
|
Chan, Arlene
|
|
2009
|
45 |
13 |
p. 2253-2265
13 p.
|
artikel
|
| 5 |
β-Catenin expression in uterine sarcomas and its relation to clinicopathological parameters
|
Kildal, Wanja
|
|
2009
|
45 |
13 |
p. 2412-2417
6 p.
|
artikel
|
| 6 |
Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids
|
Lobjois, Valérie
|
|
2009
|
45 |
13 |
p. 2402-2411
10 p.
|
artikel
|
| 7 |
Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?
|
Ohorodnyk, Pavlo
|
|
2009
|
45 |
13 |
p. 2249-2252
4 p.
|
artikel
|
| 8 |
Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients
|
Fiebrich, Helle-Brit
|
|
2009
|
45 |
13 |
p. 2312-2315
4 p.
|
artikel
|
| 9 |
Cutaneous melanoma mortality starting to change: A study of trends in Northern Ireland
|
Montella, Anthony
|
|
2009
|
45 |
13 |
p. 2360-2366
7 p.
|
artikel
|
| 10 |
Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer
|
Jullumstrø, Eivind
|
|
2009
|
45 |
13 |
p. 2383-2390
8 p.
|
artikel
|
| 11 |
Editorial board
|
|
|
2009
|
45 |
13 |
p. ii-
1 p.
|
artikel
|
| 12 |
EJC NEWS ISSUE 13, 2009
|
|
|
2009
|
45 |
13 |
p. 2229-2233
5 p.
|
artikel
|
| 13 |
Immunotherapy for malignant melanoma – Tracing Ariadne’s thread through the labyrinth
|
Grange, John M.
|
|
2009
|
45 |
13 |
p. 2266-2273
8 p.
|
artikel
|
| 14 |
Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model
|
Charasson, Virginie
|
|
2009
|
45 |
13 |
p. 2391-2401
11 p.
|
artikel
|
| 15 |
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
|
Montemurro, M.
|
|
2009
|
45 |
13 |
p. 2293-2297
5 p.
|
artikel
|
| 16 |
Palliative chemotherapy: Do we need yet another end-point?
|
van Meerbeeck, Jan P.
|
|
2009
|
45 |
13 |
p. 2234-2235
2 p.
|
artikel
|
| 17 |
PDGFR inhibition in brain tumours – Oft expectation fails where most it promises
|
Raymond, Eric
|
|
2009
|
45 |
13 |
p. 2236-2238
3 p.
|
artikel
|
| 18 |
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
|
Soria, J.C.
|
|
2009
|
45 |
13 |
p. 2333-2341
9 p.
|
artikel
|
| 19 |
Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
|
Vergote, I.
|
|
2009
|
45 |
13 |
p. 2324-2332
9 p.
|
artikel
|
| 20 |
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
|
Thomas, Fabienne
|
|
2009
|
45 |
13 |
p. 2316-2323
8 p.
|
artikel
|
| 21 |
Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer
|
Das, Kakoli
|
|
2009
|
45 |
13 |
p. 2239-2248
10 p.
|
artikel
|
| 22 |
Prognostic factors and outcomes for osteosarcoma: An international collaboration
|
Pakos, Emilios E.
|
|
2009
|
45 |
13 |
p. 2367-2375
9 p.
|
artikel
|
| 23 |
Regulatory aspects of genetic research with residual human tissue: Effective and efficient data coding
|
Schmidt, Marjanka K.
|
|
2009
|
45 |
13 |
p. 2376-2382
7 p.
|
artikel
|
| 24 |
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study
|
Scagliotti, Giorgio V.
|
|
2009
|
45 |
13 |
p. 2298-2303
6 p.
|
artikel
|
| 25 |
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium
|
Geoerger, Birgit
|
|
2009
|
45 |
13 |
p. 2342-2351
10 p.
|
artikel
|
| 26 |
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?
|
Brauch, Hiltrud
|
|
2009
|
45 |
13 |
p. 2274-2283
10 p.
|
artikel
|
| 27 |
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation
|
Carlisi, Daniela
|
|
2009
|
45 |
13 |
p. 2425-2438
14 p.
|
artikel
|
| 28 |
The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer
|
Pinheiro, Céline
|
|
2009
|
45 |
13 |
p. 2418-2424
7 p.
|
artikel
|
| 29 |
Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer
|
Straver, M.E.
|
|
2009
|
45 |
13 |
p. 2284-2292
9 p.
|
artikel
|
Tijdschrift beschrijving